

# BIOVECTRA STARTS CONSTRUCTION TO EXPAND CHARLOTTETOWN FACILITY

## BioVectra Inc. - Press Release

*Charlottetown, PE - June 11, 2014* - BioVectra, a specialized manufacturer and developer of pharmaceutical ingredients for the global marketplace, has commenced the expansion of one of its Prince Edward Island facilities, located at 11 Aviation Avenue, adjacent to the Charlottetown airport.

BioVectra is in the process of constructing a 13,000-square-foot expansion at the Regis and Joan Duffy Biopharmaceutical Centre in the City's capital. The addition will address current and future space requirements for its growing employee base, which has grown from 140 employees in 2012, to an expected 250 employees by the end of 2014. The new construction area will be comprised primarily of laboratory, offices, workstations, and amenity space.

In conjunction with its need for expanded space, current office and lab areas at the facility are also being renovated to address new equipment and meeting configuration requirements. Completion of the \$3.8 million project is expected by November, 2014, and is currently utilizing the services of a number of local contracting companies.

"We are pleased that our business growth has created new jobs at BioVectra, and we are investing in establishing proper workspace for our employees, and support services for our clients," said Ron Keefe, CEO of BioVectra. "We are continuing to grow the business with existing and new customers, requiring new skilled employees in key areas such as manufacturing, quality control, quality assurance, engineering, and maintenance functions," said Keefe.

### **About BioVectra Inc.**

BioVectra is a supplier to the global pharmaceutical industry, operating from three, FDA-inspected facilities in Prince Edward Island, Canada. The company is proficient in synthetic organic chemistry, natural extraction of bioactive compounds, PEGylation and conjugation chemistry, and fermentation of chemical and biologic molecules. BioVectra has submitted 10 product filings, including ANDA, DMF, VMF, and CMC section preparations for both the U.S. FDA and Health Canada. These filings have been made for both synthetic and biologic molecules, and include a human injectable API, as well as a final drug product.

### **For more information, please contact:**

**Heather Delage**  
**Director, Sales & Marketing**

*hdelage@biovectra.com*

**T: (866) 883-2872 / (902) 566-9116**

**[info@biovectra.com](mailto:info@biovectra.com)**



*For more information, please visit us at: [www.biovectra.com](http://www.biovectra.com)*